Deepak Cyril D'Souza1, Jose A Cortes-Briones1, Mohini Ranganathan1, Halle Thurnauer1, Gina Creatura1, Toral Surti1, Beata Planeta2, Alexander Neumeister3, Brian Pittman4, Marc Normandin5, Michael Kapinos2, Jim Ropchan2, Yiyun Huang2, Richard E Carson2, Patrick D Skosnik1. 1. Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT, USA; Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 2. Department of Radiology, Yale University School of Medicine, New Haven, CT, USA. 3. Molecular Imaging Program for Mood and Anxiety Disorders, New York University Langone Medical Center, USA. 4. Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 5. Harvard University, Massachusetts General Hospital, Boston, MA.
Abstract
BACKGROUND: The widespread use of cannabis, the increasing legalization of "medical" cannabis, the increasing potency of cannabis and the growing recreational use of synthetic cannabinoid 1 receptor (CB1R) full agonists underscores the importance of elucidating the effects of cannabinoids on the CB1R system. Exposure to cannabinoids is known to result in CB1R downregulation. However, the precise time course of changes in CB1R availability in cannabis dependent subjects (CDs) following short and intermediate term abstinence has not been determined. METHODS: Using High Resolution Research Tomography (HRRT) and [11C]OMAR, CB1R availability as indexed by the volume of distribution (VT) [11C]OMAR was measured in male CDs (n=11) and matched healthy controls (HCs) (n=19). CDs were scanned at baseline (while they were neither intoxicated nor in withdrawal), and after 2 days and 28 days of monitored abstinence. HCs were scanned at baseline and a subset (n=4) was rescanned 28 days later. RESULTS: Compared to HCs, [11C]OMAR VT was 15% lower in CDs (effect size Cohen's d=-1.11) at baseline in almost all brain regions. However, these group differences in CB1R availability were no longer evident after just 2 days of monitored abstinence from cannabis. There was a robust negative correlation between CB1R availability and withdrawal symptoms after 2 days of abstinence. Finally, there were no significant group differences in CB1R availability in CDs after 28 days of abstinence. CONCLUSIONS: Cannabis dependence is associated with CB1R downregulation, which begins to reverse surprisingly rapidly upon termination of cannabis use and may continue to increase over time.
BACKGROUND: The widespread use of cannabis, the increasing legalization of "medical" cannabis, the increasing potency of cannabis and the growing recreational use of synthetic cannabinoid 1 receptor (CB1R) full agonists underscores the importance of elucidating the effects of cannabinoids on the CB1R system. Exposure to cannabinoids is known to result in CB1R downregulation. However, the precise time course of changes in CB1R availability in cannabis dependent subjects (CDs) following short and intermediate term abstinence has not been determined. METHODS: Using High Resolution Research Tomography (HRRT) and [11C]OMAR, CB1R availability as indexed by the volume of distribution (VT) [11C]OMAR was measured in male CDs (n=11) and matched healthy controls (HCs) (n=19). CDs were scanned at baseline (while they were neither intoxicated nor in withdrawal), and after 2 days and 28 days of monitored abstinence. HCs were scanned at baseline and a subset (n=4) was rescanned 28 days later. RESULTS: Compared to HCs, [11C]OMAR VT was 15% lower in CDs (effect size Cohen's d=-1.11) at baseline in almost all brain regions. However, these group differences in CB1R availability were no longer evident after just 2 days of monitored abstinence from cannabis. There was a robust negative correlation between CB1R availability and withdrawal symptoms after 2 days of abstinence. Finally, there were no significant group differences in CB1R availability in CDs after 28 days of abstinence. CONCLUSIONS:Cannabis dependence is associated with CB1R downregulation, which begins to reverse surprisingly rapidly upon termination of cannabis use and may continue to increase over time.
Authors: Andrew G Horti; Hong Fan; Hiroto Kuwabara; John Hilton; Hayden T Ravert; Daniel P Holt; Mohab Alexander; Anil Kumar; Arman Rahmim; Ursula Scheffel; Dean F Wong; Robert F Dannals Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057
Authors: Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis Journal: J Anal Toxicol Date: 2009-10 Impact factor: 3.367
Authors: Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Harrison G Pope; Ronald Herning; Jean L Cadet; Marilyn A Huestis Journal: Addiction Date: 2009-10-05 Impact factor: 6.526
Authors: Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall Journal: Nat Rev Dis Primers Date: 2021-02-25 Impact factor: 52.329
Authors: Thibaut R Pardo-García; Nadira Yusif-Rodriguez; Guillermo Yudowski; Carmen S Maldonado-Vlaar Journal: Neurosci Lett Date: 2020-05-16 Impact factor: 3.046
Authors: Kaeli Zimmermann; Christina Walz; Raissa T Derckx; Keith M Kendrick; Bernd Weber; Bruce Dore; Kevin N Ochsner; René Hurlemann; Benjamin Becker Journal: Hum Brain Mapp Date: 2017-05-31 Impact factor: 5.038